Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04572269 · ClinicalTrials.gov registry record
Metabolomics of Obstructive Sleep Apnea
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 388
- Enrollment target
NCT04572269: Completed study, sponsored by University of Pennsylvania.
NCT04572269 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 388 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04572269 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 388 participants
- Enrollment target
Study Summary
This is an R01 funded project that focuses on the utility of metabolomics as a biomarker for OSA. Aims 1 and 3 leverages banked samples previously collected from subjects with and without OSA at the University of Pennsylvania and University of Iceland. Aim 2 is a prospective study that will collect serum samples from OSA subjects at the University of Pennsylvania and the University of Iceland.
Primary Outcome
New OSA patients, AHI\>5 will be recruited. Since this is a real-world trial, compliance of PAP usage will vary from 0 to 100%. Thus, we will be able to assess not only what metabolomic changes occur with PAP usage but also whether there is a correlation to the amount of PAP usage. Metabolomics can be used as a biomarker that correlates with duration and frequency of PAP usage. This will then be correlated to subjective and objective measures of daytime sleepiness (questionnaires + PVT) and slee
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2020-09-29 |
| Est. Completion | 2025-09-12 |
What the finished NCT04572269 record still lists
NCT04572269 is an observational study that tracks outcomes without assigning an intervention. The registered 388 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04572269 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04572269 about?
NCT04572269 is a clinical study titled "Metabolomics of Obstructive Sleep Apnea". This is an R01 funded project that focuses on the utility of metabolomics as a biomarker for OSA. Aims 1 and 3 leverages banked samples previously collected from subjects with and without OSA at the University of Pennsylvania and University of Iceland. Aim 2 is a prospective study that will collect ...
What is the current status of trial NCT04572269?
This trial is currently completed. The enrollment target is 388 participants. The study started on 2020-09-29. Estimated completion is 2025-09-12.
What interventions are being tested in trial NCT04572269?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04572269?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
- NCT05157880 · 388 participants · NA
Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers
- NCT05748613 · 388 participants · NA
Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's
- NCT06374277 · 388 participants · NA
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI